Abstract: The object of the invention is to provide a method for easily and objectively detecting mood disorders in a subject by measuring the expression levels of prescribed genes in the peripheral blood of the subject, the reliability of the detection result being high. The invention also provides a method for detecting mood disorders in a subject, the method having a step for measuring the gene expression levels of ribosomal protein genes, CDKN1C, or any combination thereof in the peripheral blood derived from the subject, and detecting whether or not the subject has mood disorders on the basis of the measurement results.

Abstract: The object of the invention is to provide a method for easily and objectively detecting mood disorders in a subject by measuring the expression levels of prescribed genes in the peripheral blood of the subject, the reliability of the detection result being high. The invention also provides a method for detecting mood disorders in a subject, the method having a step for measuring the gene expression levels of ribosomal protein genes, CDKN1C, or any combination thereof in the peripheral blood derived from the subject, and detecting whether or not the subject has mood disorders on the basis of the measurement results.

Abstract: Full-length cDNAs of plants and their uses are provided. Source plants are preferably monocot plants, more preferably poaceous plants, and most preferably rice. Vectors carrying said cDNAs and transformants containing said cDNAs or said vectors, transgenic plants containing said transformants, polypeptides encoded by said cDNAs are also provided. The full-length cDNA clones play important roles in the annotation of correct gene coding region, determination of exons and introns, comprehensive expression analysis on the transcription level and proteome analysis. Furthermore, full-length cDNA clones are industrially useful in producing plants having different properties from those of the wild type due to the inhibition of expression and functional suppression in plant bodies.

Abstract: A coated substrate for immobilizing a biological substance etc. at high density with low background value. The substrate has a cross-linking reagent represented by general formula A—L—B (wherein, A and B represent an identical or different group which reacts with an active group of the coupling agent comprising an active group, selected from an active ester group, isothiocyanate group, isocyanate group, imidazole group, carbodiimide group or aldehyde group, and wherein L is a linking group linking A and B, selected from a straight chain alkyl group, aryl group, allyl group or alkyl group having an amide group) bound thereonto by means of a coupling agent comprising an active group. An biological substance or the like is immobilized on the substrate.

Abstract: A solution for substrate spotting and spotting method for immobilizing a biological substance or various chemical substances on a substrate at high density. The solution for substrate spotting and the spotting method involve mixing a solution comprising a biological substance or chemical substance to be spotted with a solution to which an inorganic fine powder has been added as a surface tension regulating agent.

Abstract: A shuttle vector containing an yeast gene and an E. coli gene and carrying the expression control region of acid phosphatase gene of yeast, which can be recombined with various genes under control of the phosphatase promoter, to give various recombinant plasmids. The shuttle vector is useful in genetic engineering industries.

Abstract: A novel nucleic acid derivative represented by the following general formula (I) and physiologically acceptable salt thereof which are expected to have an antiviral activity: ##STR1## wherein B represents a nucleic acid base derivative; A.sup.1 and A.sup.2 represent, independently of each other, OR.sup.1 or OCOR.sup.1 ; R.sup.1 represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; l represents a number of 0 or 1; and m and n each represents an integer of 0-2; provided that when l and m are 0, n is 0 or 2.

Abstract: This invention relates to cyclobutane derivatives represented by the following general formula (1) and physiologically acceptable salts thereof: ##STR1## wherein B represents a nucleic acid base derivative, R.sup.1 and R.sup.2 independently represent hydrogen atom, dialkylaminoacyl group, 1,4-dihydro-1-methylnicotinoyl group or substituted phosphoric acid group, provided that either one of R.sup.1 and R.sup.2 is a group other than hydrogen atom.The compounds of this invention exhibit a high oral absorbability and are metabolized in vivo into the compounds of formula (1a). Accordingly, the compounds of this invention are expectedly useful as antiviral agent.

Abstract: This invention relates to novel oxetanocins represented by the following general formula (I): ##STR1## wherein R represents a group represented by ##STR2## and their pharmacologically acceptable salts which have antiviral activities.

Abstract: The present invention relates to phosphoric acid esters of oxetanocins having an antiviral activity which are represented by general formula (I): ##STR1## wherein R.sub.1 represents a phosphoric acid ester residue, X represents hydrogen, hydroxy or hydroxymethyl group, and B represents a purine base residue, and pharmacologically acceptable salts thereof.

Abstract: This invention relates to oxetanocin-related compounds represented by the following formula (I): ##STR1## [in formula (I), R.sub.1, Y and B have the following meanings: (a) R.sub.1 represents --CH.sub.2 OH or --CH.sub.2 OCO-(alkyl),(b) Y represents ##STR2## provided that R.sub.2 is --H, --OH or --CH.sub.2 OH and R.sub.3 is --H, --OH, halogen atom, --CH.sub.2 OH, lower alkyl group, --CH.sub.2 -N.sub.3, --CH.sub.2 -F, --N.sub.3, --COOH, --NH.sub.2, --CH.sub.2 OSO.sub.3 H or --CH.sub.2 OCO-(lower alkyl), and(c) B represents a residue of purine base,(d) provided that R.sub.1 and R.sub.3 cannot simultaneously represents --CH.sub.2 OH]and their salts which have activities such as an antiviral activity and the like and are expectedly useful as a pharmaceutical and the like.

Abstract: A recombinant DNA comprising 3 fragments of Hepatitis B virus DNA recombined with a vector consisting essentially of 0.31 Kb replication orgin of SV40 DNA inserted into EcoRI cleavage site of Escherichia coli plasmid which is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells, wherein each HBV DNA fragment is a 3.2 Kb BamHI fragment consisting of 1.9 Kb HBc gene and 1.3 Kb HBs gene, and said HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail, mammalian cells transformed with the recombinant DNA, and a method of production of Hepatitis B virus proteins, i.e. HBsAg and/or HBeAg. These HBV proteins have the same immunological properties as those of the natural HBV proteins originated from human blood plasma and can be used for the preparation of HBV vaccine and diagnostic reagents.

Abstract: To form a gel bed in a cylindrical column for liquid chromatography, a gel bed section is provided between upper and lower liquid-tight partition members, positioned apart from each other at upper and lower positions in the column. Liquid is continuously percolated downward through the gel bed section to form a gel bed in the gel bed section and a liquid pressure is applied onto the upper partition to move the partition member downward following a downward movement of the upper surface of the gel bed.

Abstract: To form a gel bed in a cylindrical column for liquid chromatography, a gel bed section is provided between upper and lower liquid-tight partition members, positioned apart from each other at upper and lower positions in the column. Liquid is continuously percolated downward through the gel bed section to form a gel bed in the gel bed section and a liquid pressure is applied onto the upper partition to move the partition member downward following a downward movement of the upper surface of the gel bed.

Abstract: A recombinant plasmid inserted with Hepatitis B virus gene, which comprises a plasmid vector containing a yeast gene and an E. coli gene and carrying the expression control region of the repressible acid phosphatase gene of yeast and a Hepatitis B virus gene recombined thereto under control of the phosphatase promoter, a transformed yeast which is prepared by transforming a yeast with the recombinant plasmid, and a method of the production of Hepatitis B virus surface antigen in a large scale by culturing the transformed yeast in a medium. The Hepatitis B virus surface antigen prepared by the present invention has the same immunological properties as those of the natural antigen from human blood plasma and is useful for the preparation of Hepatitis B virus vaccine and diagnostic reagents.

Abstract: A method for imparting a hydrophobic property to a fine oxide powder by treating it with an organo-polysiloxane in the presence of an alkali catalyst. The method is carried out with at least 1.5% by weight of organo-polysiloxane of molecular weight not exceeding 10,000, at least 0.5% by weight of ammonia or an aliphatic amine of a boiling point lower than 100.degree. C. and at least 1.5% by weight of water are added to a dry weight of the fine oxide powder (a quantity obtained after removal of adsorption water content under reduced pressure not exceeding 5 mmHg in mercury meter at 100.degree. to 110.degree. C.). Of these additives, the ammonia or the aliphatic amine of a boiling point not exceeding 100.degree. C. is added at a temperature not exceeding 60.degree. C. Then, after an aging process for at least 15 minutes, heating is carried out to a temperature between 60.degree. and 150.degree.0 C. for a period of at least 30 minutes. All processes are carried out under normal pressure.